Related Experiment Video
Updated: Jun 22, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
A Lipid-Sensitive Spider Peptide Toxin Exhibits Selective Anti-Leukemia Efficacy through Multimodal Mechanisms
Peng Zhang1,2,3, Wu Luo1,4, Zixin Zhang1,2,3
1The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, Hunan, 410081, China.
Abstract:
Anti-cancer peptides (ACPs) represent a promising potential for cancer treatment, although their mechanisms need to be further elucidated to improve their application in cancer therapy. Lycosin-I, a linear amphipathic peptide isolated from the venom of Lycosa singorensis, shows significant anticancer potential. Herein, it is found that Lycosin-I, which can self-assemble into a nanosphere structure, has a multimodal mechanism of action involving lipid binding for the selective and effective treatment of leukemia. Mechanistically, Lycosin-I selectively binds to the K562 cell membrane, likely due to its preferential interaction with negatively charged phosphatidylserine, and rapidly triggers membrane lysis, particularly at high concentrations. In addition, Lycosin-I induces apoptosis, cell cycle arrest in the G1 phase and ferroptosis in K562 cells by suppressing the PI3K-AKT-mTOR signaling pathway and activating cell autophagy at low concentrations. Furthermore, intraperitoneal injection of Lycosin-I inhibits tumor growth of K562 cells in a nude mouse xenograft model without causing side effects. Collectively, the multimodal effect of Lycosin-I can provide new insights into the mechanism of ACPs, and Lycosin-I, which is characterized by high potency and specificity, can be a promising lead for the development of anti-leukemia drugs.
Insights
Lycosin-I, an anti-cancer peptide, effectively treats leukemia by targeting cancer cell membranes and inducing multiple cell death pathways. This peptide shows promise as a potent and specific anti-leukemia drug candidate with minimal side effects.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Anti-cancer peptides (ACPs) offer potential cancer treatments, but their mechanisms require further study for improved therapeutic applications.
- Lycosin-I, a peptide from Lycosa singorensis venom, exhibits significant anticancer properties and self-assembles into nanospheres.
Purpose of the Study:
- To elucidate the multimodal mechanism of action of Lycosin-I in treating leukemia.
- To evaluate the therapeutic potential and specificity of Lycosin-I against K562 leukemia cells.
Main Methods:
- Investigated Lycosin-I's interaction with K562 cell membranes, including lipid binding and membrane lysis.
- Analyzed Lycosin-I's effects on apoptosis, cell cycle arrest, ferroptosis, and autophagy via the PI3K-AKT-mTOR pathway.
- Assessed Lycosin-I's in vivo efficacy and safety in a K562 xenograft mouse model.
Main Results:
- Lycosin-I selectively binds to K562 cell membranes, inducing rapid membrane lysis at high concentrations.
- At low concentrations, Lycosin-I triggers apoptosis, G1 cell cycle arrest, and ferroptosis while activating autophagy by modulating the PI3K-AKT-mTOR pathway.
- Intraperitoneal administration of Lycosin-I effectively inhibited K562 tumor growth in mice without observable side effects.
Conclusions:
- Lycosin-I exhibits a multimodal mechanism of action against leukemia, involving direct membrane disruption and induction of multiple cell death pathways.
- Lycosin-I demonstrates high potency and specificity, positioning it as a promising lead compound for developing novel anti-leukemia therapeutics.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...